- Home
- SB vs FULC Comparison
SB vs FULC Comparison
Compare SB & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- FULC
- Stock Information
- Founded
- SB 2007
- FULC 2015
- Country
- SB Monaco
- FULC United States
- Employees
- SB 941
- FULC N/A
- Industry
- SB Marine Transportation
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- SB Consumer Discretionary
- FULC Health Care
- Exchange
- SB Nasdaq
- FULC Nasdaq
- Market Cap
- SB 457.4M
- FULC 469.0M
- IPO Year
- SB 2008
- FULC 2019
- Fundamental
- Price
- SB $4.47
- FULC $9.51
- Analyst Decision
- SB Strong Buy
- FULC Buy
- Analyst Count
- SB 1
- FULC 6
- Target Price
- SB $5.00
- FULC $8.67
- AVG Volume (30 Days)
- SB 356.3K
- FULC 537.7K
- Earning Date
- SB 11-12-2025
- FULC 11-12-2025
- Dividend Yield
- SB 4.47%
- FULC N/A
- EPS Growth
- SB N/A
- FULC N/A
- EPS
- SB 0.43
- FULC N/A
- Revenue
- SB $277,509,000.00
- FULC N/A
- Revenue This Year
- SB N/A
- FULC N/A
- Revenue Next Year
- SB $13.02
- FULC N/A
- P/E Ratio
- SB $10.35
- FULC N/A
- Revenue Growth
- SB N/A
- FULC 2752.05
- 52 Week Low
- SB $3.02
- FULC $2.32
- 52 Week High
- SB $5.21
- FULC $9.70
- Technical
- Relative Strength Index (RSI)
- SB 50.63
- FULC 73.21
- Support Level
- SB $4.40
- FULC $8.33
- Resistance Level
- SB $4.53
- FULC $9.70
- Average True Range (ATR)
- SB 0.10
- FULC 0.51
- MACD
- SB -0.03
- FULC 0.17
- Stochastic Oscillator
- SB 22.50
- FULC 92.00
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.